Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04570267




Registration number
NCT04570267
Ethics application status
Date submitted
25/09/2020
Date registered
30/09/2020
Date last updated
4/10/2022

Titles & IDs
Public title
Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Scientific title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Secondary ID [1] 0 0
CSL324_1003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - CSL324
Treatment: Drugs - Placebo

Experimental: CSL324 (Low dose) - One low dose of CSL324 administered subcutaneously on Day 1

Experimental: CSL324 (High dose) - One high dose of CSL324 administered subcutaneously on Day 1

Placebo Comparator: Placebo - One dose of placebo administered subcutaneously on Day 1


Other interventions: CSL324
Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection

Treatment: Drugs: Placebo
Sterile solution of CSL324 formulation buffer for injection
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Maximum concentration (Cmax) of CSL324 in serum
Timepoint [1] 0 0
From Day 1 to Day 56
Primary outcome [2] 0 0
Area under the concentration-time curve from time 0 extrapolated to time infinity (AUC0-inf) of CSL324 in serum
Timepoint [2] 0 0
From Day 1 to Day 56
Primary outcome [3] 0 0
Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL324 in serum
Timepoint [3] 0 0
From Day 1 to Day 56
Secondary outcome [1] 0 0
Number of subjects with treatment-emergent adverse events (TEAEs) by incidence, by severity, and by causality
Timepoint [1] 0 0
Up to Day 56
Secondary outcome [2] 0 0
Percentage of subjects with TEAEs by incidence, by severity, and by causality
Timepoint [2] 0 0
Up to Day 56
Secondary outcome [3] 0 0
Number of subjects with adverse events localized to the administration site by incidence, by severity, and by causality
Timepoint [3] 0 0
Up to Day 7
Secondary outcome [4] 0 0
Percentage of subjects with adverse events localized to the administration site by incidence, by severity, and by causality
Timepoint [4] 0 0
Up to Day 7
Secondary outcome [5] 0 0
Time to reach Cmax (Tmax) for CSL324 in serum
Timepoint [5] 0 0
From Day 1 to Day 56
Secondary outcome [6] 0 0
Terminal half-life (t1/2) for CSL324 in serum
Timepoint [6] 0 0
From Day 1 to Day 56
Secondary outcome [7] 0 0
Apparent clearance (CL/F) for CSL324 in serum
Timepoint [7] 0 0
From Day 1 to Day 56
Secondary outcome [8] 0 0
Apparent volume of distribution (Vz/F) for CSL324 in serum
Timepoint [8] 0 0
From Day 1 to Day 56
Secondary outcome [9] 0 0
Number of subjects with or without anti-CSL324 antibodies
Timepoint [9] 0 0
Up to Day 56
Secondary outcome [10] 0 0
Percentage of subjects with or without anti-CSL324 antibodies
Timepoint [10] 0 0
Up to Day 56

Eligibility
Key inclusion criteria
- Healthy male or female Japanese or White subjects aged 20 and 55 years, inclusive

- Body weight of at least 45 kg to 100 kg, inclusive

- Body mass index of 18.0 to 32.0 kg/m2, inclusive
Minimum age
20 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- A clinically significant medical condition, disorder, or disease of any organ system.

- Concurrent diagnosis of malignancy or history of malignancy (except for nonmelanoma
skin cancer or cervical carcinoma in situ that has been adequately treated with no
evidence of recurrence for at least 3 months before Screening).

- Immunosuppressive conditions and / or currently taking immunosuppressive or
immunomodulative therapy.

- Clinically significant abnormalities on physical examination, vital signs, or
laboratory assessments, or neutropenia (defined as absolute neutrophil count < 2.0 ×
109/L).

- History of chronic or recurrent infections, clinical signs of active infection and /
or fever, current / history of serious infection or hospitalized or received IV
antibiotics for an infection in previous 2 months.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/12/2021
Sample size
Target
Accrual to date
Final
32
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Scientia Clinical Research Ltd - Randwick
Recruitment postcode(s) [1] 0 0
- Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
CSL Behring
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Study CSL324_1003 is a single center, randomized, double-blind, placebo-controlled study
designed to characterize and compare the PK properties and safety of a single subcutaneous
dose of CSL324 in healthy Japanese and White subjects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04570267
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
CSL Behring
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries